Hospital Quironsalud Zaragoza

Zaragoza 50012

1 studies enrolling now · 7 studies all time

What they study most

BRAF V600E-mutant Metastatic Colorectal Cancer, Colorectal Neoplasms, Fabry Disease, Gaucher Disease, Gaucher Disease, Type 1

Studies at this site

• A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer — Recruiting now
• A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease — Running, not enrolling
• A Gene Therapy Study in Patients With Gaucher Disease Type 1 — Completed
• Long Term Follow-up Study of Type-1 Gaucher Subjects Post FLT201 Dose (GALILEO-2) — Running, not enrolling
• Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease — Completed
• Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer — Completed
• Study of the Effect of Velaglucerase Alfa (VPRIV®) on Bone-related Pathology in Treatment-naïve Participants With Type 1 Gaucher Disease — Completed